263 papers found
Refreshing results…
PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma
Fully automated workflow for integrated sample digestion and Evotip loading enabling high-throughput clinical proteomics
Restoring tumor immunogenicity with dendritic cell reprogramming
Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy
Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report
Seasonal variation in effect of anti‐ PD ‐1 initiation on overall survival among patients with advanced melanoma
Clinical advances and ongoing trials on mRNA vaccines for cancer treatment
COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis
Abstract CT535: High clinical efficacy in poor prognosis patients with metastatic melanoma treated with an IDO/PD-L1 peptide vaccine in combination with nivolumab
LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes in patients with metastatic soft tissue sarcoma.
Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC)
Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions
Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy
Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
Real-time Monitoring of Mitochondrial Respiration in Cytokine-differentiated Human Primary T Cells
Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens
Missing publications? Read more about our data sources.